The Company’s has IPR covering the NK-cell based therapy Cellprotect through one granted patent and one PCT with priority dates during 2009 and 2007 respectively. The IP covers key elements of the manufacturing process as well as the expanded NK-cells. The 2009 application has been granted in the US and China and other countries are pending. The PCT application is designated for major markets such as EU, Japan, US, Korea and China.
In addition to the IP protection, CPNP also has extensive and in-depth know-how within the field of cell therapies and GMP manufacturing processes.